241 related articles for article (PubMed ID: 16433203)
1. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
[TBL] [Abstract][Full Text] [Related]
2. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.
Rosewich M; Schulze J; Eickmeier O; Telles T; Rose MA; Schubert R; Zielen S
Clin Exp Immunol; 2010 Jun; 160(3):403-10. PubMed ID: 20345983
[TBL] [Abstract][Full Text] [Related]
3. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
Rosewich M; Lee D; Zielen S
Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
[TBL] [Abstract][Full Text] [Related]
4. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
5. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
[TBL] [Abstract][Full Text] [Related]
7. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
[TBL] [Abstract][Full Text] [Related]
9. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
10. Effect of allergen-specific immunotherapy on platelet secretory activity in patients with grass-pollen allergy.
Kasperska-Zajac A; Brzoza Z; Rogala B
Vaccine; 2006 Nov; 24(47-48):6990-3. PubMed ID: 17011086
[TBL] [Abstract][Full Text] [Related]
11. The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy.
Bell AJ; Heath MD; Hewings SJ; Skinner MA
J Inorg Biochem; 2015 Nov; 152():147-53. PubMed ID: 26337118
[TBL] [Abstract][Full Text] [Related]
12. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
13. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.
Reeve L; Baldrick P; Hewings S; Skinner M
J Appl Toxicol; 2012 Aug; 32(8):608-16. PubMed ID: 21919021
[TBL] [Abstract][Full Text] [Related]
14. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
15. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
[TBL] [Abstract][Full Text] [Related]
16. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Worm M; Ernst D; Kraller M; Babina M
Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
[TBL] [Abstract][Full Text] [Related]
17. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
18. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
19. Reactivity of T cells with grass pollen allergen extract and allergoid.
Kahler H; Stüwe H; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 1999 Oct; 120(2):146-57. PubMed ID: 10545769
[TBL] [Abstract][Full Text] [Related]
20. Safety of ultrashort-term sit with pollen allergoids adjuvanted by monophosphoryl lipid A: a prospective Italian survey.
Crivellaro M; Senna GE; Pappacoda A; Vanzelli R; Spacal B; Marchi G; Recchia G; Makatsori M
Eur Ann Allergy Clin Immunol; 2011 Mar; 43(2):58-60. PubMed ID: 21608374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
